Friday May 25 | Seeking Alpha
Forest Laboratories (FRX) says it's decided to discontinue the...
Forest Laboratories says it's decided to discontinue the development of apadenoson, its experimental agent for cardiovascular imaging procedures.
Forest Laboratories, Inc. and Almirall to Present Aclidinium Bromide...
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Forest Laboratories, Inc.
Why Billionaire Carl Icahn Could Target This Substantially Undervalued Biotech
Billionaire activist investor Carl Icahn has made a fortune off of targeting declining biotech companies.
Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran...
Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association Annual Meeting NEW YORK -- -- Forest Laboratories, Inc.
UPDATE 1-Lundbeck keeps year outlook after Q1 lags forecasts
Danish drugmaker Lundbeck stood by its forecasts for 2012 on Wednesday despite a disappointing first quarter, when sales of its leading drug fell more sharply than expected as it loses patent protection.
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter
ALKS -3.3% WCRX +16.07% BSX +0.97% MRK +2.03% UNH -3.11% FRX -0.26% RHHBY +0.46% PFE -0.65% Edward Owens bought only one new stock and added to seven others in the first quarter of 2012.
Forest Laboratories Given "Neutral" Rating at Zacks
's stock had its "neutral" rating restated by Zacks in a report issued on Monday.